Produktbeschreibung
CPB504 is a 1+1 bivalent bispecific checkpoint inhibitor antibody that targets both mouse programmed cell death protein-1 (PD-1, CD279) and mouse cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) to enhance T-cell-mediated antitumor immunity. CPB504 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity. This bispecific is designed to simultaneously bind PD-1 and CTLA-4 on T cells, particularly tumor-infiltrating lymphocytes, to engage both checkpoints on the same or neighboring T cells and provide coordinated dual checkpoint blockade within the tumor microenvironment. Blocking PD-1 prevents interaction with PD-L1/PD-L2 and reverses PD-1-mediated inhibitory signaling, restoring T-cell activation, proliferation, and effector function against tumor cells. Concurrent CTLA-4 blockade reduces competition with CD28 for CD80/CD86, enhancing costimulatory signaling and promoting expansion and priming of effector T cells, further amplifying antitumor responses.
* MwSt. und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
